Long-term safety of imatinib for LAM
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests the long-term safety and tolerability of the drug imatinib in women with LAM, a rare lung disease that causes cysts. It may help stabilize lung function over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 64 years old.
- You have a confirmed or possible diagnosis of LAM (a rare lung disease with cysts).
- Your lung function tests meet certain numbers: either your DLCO (gas exchange) is above 20% predicted and your FVC (total lung volume) is below 90%, or your FEV1 (airflow) is between 30% and 90% predicted after using a bronchodilator.
- You are willing to avoid grapefruit juice and St. John's wort during the study.
- You are not pregnant, breastfeeding, or planning pregnancy, and you have not had or do not plan a lung transplant or surgery.
- You are not taking certain medications that can interact with imatinib (like some antifungals, antibiotics, HIV meds, seizure meds, or others).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
This Phase 1/2 study tests whether breathing in albuterol can improve symptoms or lung function in people with lymphangioleiomyomatosis (LAM). It’s mainly about safety and early signs of benefit by targeting airflow problems.
This study looks at the natural history and disease process of lymphangioleiomyomatosis (LAM), a rare lung disease that mostly affects women. It may help understand how LAM progresses and how it affects daily life, and may include exercise testing and other evaluations.
This trial studies people with advanced or metastatic gastrointestinal stromal tumor (GIST) who have been on the drug imatinib for 10 years with stable, non-growing disease. The goal is to see how effective it is to keep imatinib going after this long period.
This trial tests whether a special inhaled form of the medicine imatinib can help people with advanced lung scarring or high blood pressure in the lungs. It is designed for those who are on the path to a lung transplant or already received one.
This Phase 2 trial studies how to adjust and monitor imatinib (a targeted cancer medicine) based on drug levels in the blood. It may help people with GIST that has certain KIT or PDGFRA mutations but not the PDGFRA D842V type.
Hear when a new Lymphangioleiomyomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.